First AD

Second AD

Clinical Impact of Patient-Reported Outcomes in cGVHD

Video content above is prompted by the following:

What is the role of patient-reported outcomes (PROs) to measure symptom burden, adverse effect burden, and quality of life and treatment response in cGVHD in your practice? 

Which PRO measures are most useful for evaluating disease improvement in cGVHD?

What do results from recently published PRO data for belumosudil show (Lee SJ, et al. 

Also summarize data with ruxolitinib (Zeiser R, et al. 

. 2021) and FDA analysis of ibrutinib PRO data (King-Kallimanis BL, et al. 

How can available PRO data be utilized in clinical practice to improve quality of life of patients with cGVHD?

Video Series

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

My Treatment Approach: Optimizing Treatment for Chronic GVHD

Medical experts discuss the role of patient-reported outcomes in cGVHD. 